Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 16;24(2):317-9.
doi: 10.1097/QAD.0b013e3283315697.

N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations

Nicolas Sluis-Cremer  1 , Katie Moore, Jessica Radzio, Secondo Sonza, Gilda Tachedjian
Affiliations

N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations

Nicolas Sluis-Cremer et al. AIDS. .

Abstract

We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None to declare

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007;4:e335. - PMC - PubMed
    1. Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol. 2008;82:3261–3270. - PMC - PubMed
    1. Cane PA, Green H, Fearnhill E, Dunn D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 2007;21:447–455. - PubMed
    1. Santos AF, Lengruber RB, Soares EA, Jere A, Sprinz E, Martinez AM, et al. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE. 2008;3:e1781. - PMC - PubMed
    1. Waters JM, O'Neal W, White KL, Wakeford C, Lansdon EB, Harris J, et al. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther. 2009;14:231–239. - PubMed

Publication types